7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Osteoporotic Fractures D058866 1 associated lipids
Hemangioma, Capillary D018324 1 associated lipids
Dentin Dysplasia D003805 1 associated lipids
Neoplasms, Squamous Cell D018307 1 associated lipids
Cleidocranial Dysplasia D002973 1 associated lipids
Prediabetic State D011236 1 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Neoplastic Syndromes, Hereditary D009386 1 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Canon J et al. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. 2012 Breast Cancer Res. Treat. pmid:22926264
Yoon WJ et al. Sargachromanol G regulates the expression of osteoclastogenic factors in human osteoblast-like MG-63 cells. 2012 Food Chem. Toxicol. pmid:22727857
Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. 2011 Nov-Dec Clin. Exp. Rheumatol. pmid:22032557
Arikan F et al. C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. 2011 Mar-Apr Int J Oral Maxillofac Implants pmid:21483881
Crespi R et al. Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. 2011 Jul-Aug Int J Oral Maxillofac Implants pmid:21841997
Franke S et al. Advanced glycation end products affect growth and function of osteoblasts. 2011 Jul-Aug Clin. Exp. Rheumatol. pmid:21906430
Rezg R et al. Inhibitors of vascular calcification as potential therapeutic targets. 2011 Jul-Aug J. Nephrol. pmid:21688249
Reyes-García R et al. [Cardiovascular disease and bone metabolism]. 2011 Aug-Sep Endocrinol Nutr pmid:21775224
Wang Y et al. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. 2011 Mol. Cell. Endocrinol. pmid:21291955
Szulc P et al. Cortical bone status is associated with serum osteoprotegerin concentration in men: the STRAMBO study. 2011 J. Clin. Endocrinol. Metab. pmid:21565793
Zhang M et al. EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair. 2011 J. Bone Miner. Res. pmid:20939055
Zhang Y et al. Enhanced osteoclastic resorption and responsiveness to mechanical load in gap junction deficient bone. 2011 PLoS ONE pmid:21897843
Tanaka H et al. Expression of RANKL/OPG during bone remodeling in vivo. 2011 Biochem. Biophys. Res. Commun. pmid:21771583
Meulman T et al. Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats. 2011 J. Periodont. Res. pmid:21726226
Yang L et al. Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation. 2011 Chin. Med. J. pmid:22088466
Reinhard H et al. Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. 2011 Cardiovasc Diabetol pmid:21801376
Jabbar S et al. Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. 2011 J. Periodont. Res. pmid:20731767
Curl L and Sampson W The presence of TNF-alpha and TNFR1 in aseptic root resorption. A preliminary study. 2011 Aust Orthod J pmid:22372265
Pepene CE et al. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism. 2011 Clin Invest Med pmid:21810381
Sheng L et al. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system]. 2011 Zhongguo Zhong Xi Yi Jie He Za Zhi pmid:21812275
Yang XY et al. [Influence of surface modification of titanium on OPG/RANKL mRNA expression in MG-63 human osteoblast-like cells]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21868322
Malliga DE et al. The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology - a review. 2011 Wien Med Wochenschr pmid:21870142
Guo HL et al. [Experimental study on the mechanism of icariin improving human osteoblasts proliferation and the expression of OPG protein]. 2011 Zhongguo Gu Shang pmid:21870401
McGrath EE OPG/RANKL/RANK pathway as a therapeutic target in cancer. 2011 J Thorac Oncol pmid:21849854
Findlay DM and Atkins GJ Relationship between serum RANKL and RANKL in bone. 2011 Osteoporos Int pmid:21850548
Christoforidis A et al. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. 2011 Haemophilia pmid:20825502
Lommi JI et al. High-density lipoproteins (HDL) are present in stenotic aortic valves and may interfere with the mechanisms of valvular calcification. 2011 Atherosclerosis pmid:21917259
Embree M et al. Role of subchondral bone during early-stage experimental TMJ osteoarthritis. 2011 J. Dent. Res. pmid:21917603
Hope S et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. 2011 J Psychiatr Res pmid:21889167
Shin M et al. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. 2011 Carcinogenesis pmid:21890459
Grigoropoulou P et al. The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. 2011 Curr. Med. Chem. pmid:21919846
Riancho JA and Delgado-Calle J [Osteoblast-osteoclast interaction mechanisms]. 2011 Reumatol Clin pmid:21924211
Peng S et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. 2011 Bone pmid:21925296
Fan R et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells. 2011 Chin. Med. J. pmid:21933620
To M et al. Osteoprotegerin in sputum is a potential biomarker in COPD. 2011 Chest pmid:21127170
Osorio A et al. Mineral-bone metabolism markers in young hemodialysis patients. 2011 Clin. Biochem. pmid:21933667
Witasp A et al. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. 2011 Eur. J. Clin. Invest. pmid:21128937
Khoshniat S et al. Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium. 2011 Bone pmid:21147284
Durual S et al. Titanium nitride oxide coating on rough titanium stimulates the proliferation of human primary osteoblasts. 2011 Clin Oral Implants Res pmid:21087318
Ashley DT et al. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. 2011 Metab. Clin. Exp. pmid:21087777
Campbell GM et al. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. 2011 Osteoporos Int pmid:20480144
Tekkesin MS et al. The role of RANK/RANKL/OPG signalling pathways in osteoclastogenesis in odontogenic keratocysts, radicular cysts, and ameloblastomas. 2011 Head Neck Pathol pmid:21643971
Jiang JQ et al. Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder. 2011 Nephrology (Carlton) pmid:21649792
Choi EM Honokiol isolated from Magnolia officinalis stimulates osteoblast function and inhibits the release of bone-resorbing mediators. 2011 Int. Immunopharmacol. pmid:21621646
Ueland T et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. 2011 J. Intern. Med. pmid:21623962
Wheater G et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. 2011 Osteoporos Int pmid:21625887
Hossein-nezhad A et al. The influence of folic acid supplementation on maternal and fetal bone turnover. 2011 J. Bone Miner. Metab. pmid:20602129
Colombini A et al. Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing. 2011 Int Orthop pmid:20623281
Kanayama K et al. Osteoclast and osteoblast activities on carbonate apatite plates in cell cultures. 2011 J Biomater Appl pmid:20624844
Galliera E et al. Circulating OPG levels are reduced following infliximab treatment and correlate with CRP levels: is serum OPG a potential marker of IBD disease activity? 2011 Inflamm. Bowel Dis. pmid:21433226
Hou L et al. Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts. 2011 Acta Vet. Scand. pmid:21435269
Baloul SS et al. Mechanism of action and morphologic changes in the alveolar bone in response to selective alveolar decortication-facilitated tooth movement. 2011 Am J Orthod Dentofacial Orthop pmid:21435543
Wang AY Consequences of chronic inflammation in peritoneal dialysis. 2011 Semin. Nephrol. pmid:21439430
Ikeda K et al. Conditional expression of constitutively active estrogen receptor α in osteoblasts increases bone mineral density in mice. 2011 FEBS Lett. pmid:21439958
Teramachi J et al. Adenosine abolishes MTX-induced suppression of osteoclastogenesis and inflammatory bone destruction in adjuvant-induced arthritis. 2011 Lab. Invest. pmid:21339747
Katz J et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. 2011 Int J Oral Maxillofac Surg pmid:21396799
Bitto A et al. Genistein aglycone effect on bone loss is not enhanced by supplemental calcium and vitamin D3: a dose ranging experimental study. 2011 Phytomedicine pmid:21397481
Di Bartolo BA et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. 2011 Cardiovasc. Res. pmid:21447702
Ho TY et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. 2011 Bone pmid:21419242
Vishvanath A et al. Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL). 2011 Histopathology pmid:22034880
Vidal C et al. Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density. 2011 J. Mol. Endocrinol. pmid:21994215
Hemingway F et al. In vitro generation of mature human osteoclasts. 2011 Calcif. Tissue Int. pmid:21960377
Dimitriadis K et al. Exercise blood pressure response is related to asymmetric dimethylarginine and osteoprotegerin in hypertension. 2011 Int. J. Cardiol. pmid:21975354
Yao Y et al. Synergistic enhancement of new bone formation by recombinant human bone morphogenetic protein-2 and osteoprotegerin in trans-sutural distraction osteogenesis: a pilot study in dogs. 2011 J. Oral Maxillofac. Surg. pmid:22018252
Brown TT et al. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. 2011 Antivir. Ther. (Lond.) pmid:22024522
Mödder UI et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. 2011 J. Bone Miner. Res. pmid:20499362
Hsieh TP et al. Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE(2) synthesis. 2011 Phytomedicine pmid:20554188
Zheng Y et al. Vitamin D deficiency promotes prostate cancer growth in bone. 2011 Prostate pmid:21541977
Yener S et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? 2011 J. Endocrinol. Invest. pmid:20530985
de Souza JA et al. Expression of suppressor of cytokine signaling 1 and 3 in ligature-induced periodontitis in rats. 2011 Arch. Oral Biol. pmid:21511249
Claro T et al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. 2011 PLoS ONE pmid:21525984
Giro G et al. Influence of estrogen deficiency on bone around osseointegrated dental implants: an experimental study in the rat jaw model. 2011 J. Oral Maxillofac. Surg. pmid:21530046
Won KY et al. RANK signalling in bone lesions with osteoclast-like giant cells. 2011 Pathology pmid:21532526
Naot D et al. Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. 2011 Bone pmid:21515435
Aydin H et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. 2011 Minerva Endocrinol. pmid:21519319
Huang CH et al. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. 2011 Rheumatology (Oxford) pmid:20974615
Pepene CE et al. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. 2011 Eur. J. Endocrinol. pmid:20974706
Sipos W et al. OPG-Fc treatment in growing pigs leads to rapid reductions in bone resorption markers, serum calcium, and bone formation markers. 2011 Horm. Metab. Res. pmid:22161252
Akinci B et al. Increased osteoprotegerin levels in women with previous gestational diabetes developing metabolic syndrome. 2011 Diabetes Res. Clin. Pract. pmid:20970873
Toffoli B et al. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. 2011 Mol. Cell. Endocrinol. pmid:20832449
Qu Z et al. Effect of enamel matrix derivative on proliferation and differentiation of osteoblast cells grown on the titanium implant surface. 2011 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:21232997
Rauch A et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. 2011 FASEB J. pmid:21233489
Ueland T et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. 2011 Circ Heart Fail pmid:21216833
Tang T et al. Effect of water-soluble P-chitosan and S-chitosan on human primary osteoblasts and giant cell tumor of bone stromal cells. 2011 Biomed Mater pmid:21205994
Attia EA et al. Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. 2011 Int. J. Dermatol. pmid:21182499
Sun Z and Tee BC Molecular variations related to the regional differences in periosteal growth at the mandibular ramus. 2011 Anat Rec (Hoboken) pmid:21157918
Wang SY et al. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. 2011 J. Rheumatol. pmid:21362762
Preshaw PM and Taylor JJ How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? 2011 J. Clin. Periodontol. pmid:21323705
Basu R et al. Effects of physiological variations in circulating insulin levels on bone turnover in humans. 2011 J. Clin. Endocrinol. Metab. pmid:21325461
Kamiya N et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. 2011 Int. J. Clin. Oncol. pmid:21327451
Eslami B et al. Reduced osteoclastogenesis and RANKL expression in marrow from women taking alendronate. 2011 Calcif. Tissue Int. pmid:21327765
Jørgensen L et al. Serum osteoprotegerin levels are related to height loss: the Tromsø Study. 2011 Eur. J. Epidemiol. pmid:21331661
Yuan H et al. Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis. 2011 J. Clin. Periodontol. pmid:22092474
Feng Z et al. An oligodeoxynucleotide with promising modulation activity for the proliferation and activation of osteoblast. 2011 Int J Mol Sci pmid:21731457
Peng S et al. Osteoprotegerin deficiency attenuates strontium-mediated inhibition of osteoclastogenesis and bone resorption. 2011 J. Bone Miner. Res. pmid:21611968
Mai QG et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. 2011 J. Cell. Biochem. pmid:21618594
Garcia VG et al. Treatment of experimental periodontal disease with antimicrobial photodynamic therapy in nicotine-modified rats. 2011 J. Clin. Periodontol. pmid:22092666
Kornak U Animal models with pathological mineralization phenotypes. 2011 Joint Bone Spine pmid:21550285
Santini D et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. 2011 PLoS ONE pmid:21559440
Mariúba MV et al. Effect of triiodothyronine on the maxilla and masseter muscles of the rat stomatognathic system. 2011 Braz. J. Med. Biol. Res. pmid:21584440

Table of Content